Early stage Alzheimer's treatments need government action for success: report
By CelebUD Newsroom —
Emerging medical breakthroughs could soon allow Canadian patients to access targeted pharmaceuticals designed to slow the progression of Alzheimer’s disease, yet severe structural bottlenecks in provincial healthcare systems threaten to block people from receiving them in time. A comprehensive health report published this month demands that federal, provincial, and territorial governments accelerate clinical diagnostic pathways and expand specialist infrastructure before two newly approved therapies reach the Canadian market over the coming 12 to 18 months.
The Promise and Limits of Emerging Alzheimer's Therapies
Dementia serves as an overarching classification for debilitating declines in memory, language comprehension, and problem-solving abilities that currently impact roughly one per cent of Canada's population. Alzheimer’s disease represents the single most prevalent driver of this cognitive deterioration. For decades, clinicians lacked disease-modifying options, but recent pharmaceutical advances have introduced targeted interventions intended to blunt cognitive decline.
Health Canada has granted formal regulatory approval to two innovative medications: lecanemab, developed and commercialized jointly by Biogen and Eisai Co. under the brand name Leqembi, and donanemab, brought to market by Eli Lilly as Kisunla. Concurrently, the Canada Drug Agency has issued a positive recommendation for the public reimbursement of lecanemab and delivered a favourable draft recommendation regarding donanemab.
| Therapy Name | Brand Name | Manufacturers | Regulatory Status (Canada) | CDA Recommendation |
|---|---|---|---|---|
| Lecanemab | Leqembi | Eisai Co. & Biogen | Approved by Health Canada | Recommended for public reimbursement |
| Donanemab | Kisunla | Eli Lilly | Approved by Health Canada | Positive draft recommendation |
While these therapeutic agents cannot reverse or entirely arrest cognitive deterioration, clinical evidence demonstrates they can meaningfully decelerate neurodegenerative decline, thereby prolonging independent functioning and preserving quality of life for individuals during the initial phases of the condition.
The Diagnostic Race Against Time
Despite their medical promise, these therapies carry exceptionally strict eligibility windows. Medical specialists emphasize that the treatments are designed exclusively for cognitive impairment caused directly by Alzheimer’s disease, functioning safely and effectively solely during the mildest, earliest stages.
“They’re only for the type of dementia that’s caused by Alzheimer’s, and even among people with Alzheimer’s, they’re only effective and safe in the very early stages of Alzheimer’s, like when we can just begin to recognize it in the clinic. If it’s someone who’s eligible for these new treatments for Alzheimer’s where the treatment is limited to people in mild stages, there’s a bit of a ticking clock.”
This assessment from Dr. Eric Smith, who directs the Cognitive Neurosciences Clinic at the University of Calgary, underscores the vulnerability facing Canadian patients. Today, prolonged systemic backlogs mean individuals frequently wait between 18 and 24 months—or even longer depending on geographical location—simply to secure a formal diagnosis. Given that the therapeutic window closes as neurodegeneration advances, standard diagnostic delays could render many eligible Canadians permanently disqualified from receiving the drugs.
The Seven Policy Priorities for Dementia Reform
Addressing these critical bottlenecks, the newly released report outlines seven fundamental recommendations aimed at provincial health ministries, federal authorities, and public drug benefit programs. Key pillars of these demands include:
- Securing public reimbursement: Ensuring public drug plans cover the substantial costs associated with these treatments so accessibility is not determined by personal wealth.
- Building a coordinated care corridor: Unifying fragmented assessment, testing, and treatment protocols into a seamless, synchronized dementia healthcare pathway.
- Expanding diagnostic capacity: Equipping primary care clinics and regional centres with the clinical tools and training necessary to detect early cognitive decline quickly.
- Upgrading diagnostic infrastructure: Increasing clinical availability for specialized MRI scanning, infusion facilities, and ongoing post-treatment monitoring.
Advocates argue that Canada's approach to cognitive illness suffers from systemic fragmentation when evaluated alongside other chronic disease frameworks. Ngozi Iroanyah, director of health equity and access at the Alzheimer Society of Ontario, highlighted that cancer care operates along an established, supportive corridor, whereas dementia patients frequently receive a diagnosis without structured guidance or navigational resources.
“When we compare it, for example, to the cancer care path that we have in Canada and Ontario, you get a diagnosis of cancer and you’re ushered into this system. For dementia, we don’t have that corridor, you’re just told you have dementia, you’re supposed to just sort of, ‘off you go’ and hope that you can figure it out along the way.”
“So thinking about now that we have this wonderful new treatment for early-stage dementia, how do we then implement it as part of the dementia care pathway which we don’t currently have.”
Iroanyah also pointed out that systemic barriers disproportionately hurt individuals living in rural or remote areas and people from disadvantaged socioeconomic backgrounds, who regularly face geographic and economic hurdles accessing infusion suites and specialized MRI facilities necessary for patient safety checks.
Public Education and Prevention Measures
Beyond hospital and clinic operations, specialists caution that general misconceptions regarding brain health frequently impede early clinical intervention. Normalizing cognitive loss as an inevitable byproduct of aging often deters families from seeking timely evaluations.
Sylvia Villeneuve, director of the Centre for Studies on Prevention of Alzheimer’s Disease in Quebec, noted that while minor lapses happen as people age, significant memory impairment represents a clinical condition requiring medical attention rather than dismissive acceptance.
“A lot of people say, ‘Hey, your memory impairment with aging is normal,’ there is a stage where it’s no longer normal. I think that we also kind of, you know, pass this information so when do we think that it’s more in line of a start of Alzheimer’s disease versus kind of normal aging.”
Villeneuve underscored that broader public health strategies must simultaneously prioritize proactive risk reduction. She stressed that encouraging routine physical exercise, cognitive stimulation through ongoing education, and social connection helps delay symptom onset, even if lifestyle changes alone cannot entirely eliminate genetic risk.
“You can do all the sport in your life, that doesn’t mean that you’re not going to have Alzheimer’s disease, but you could at least reduce your risk of eventually having the disease or maybe postpone it for a few years.”
Government Responses Across Jurisdictions
In response to growing pressure, government representatives maintain that initial preparatory measures are taking shape across the country:
- Alberta: A representative from the Ministry of Primary and Preventative Health Services stated that provincial officials are collaborating alongside Alberta Precision Laboratories and frontline practitioners to establish diagnostic testing protocols, confirm patient eligibility standards, and create therapy administration frameworks.
- Ontario: The Ministry of Health pointed to historical expenditures in dementia support networks, highlighting a targeted $4.1 million allocation designed to broaden care services while health bodies review therapies through structured, evidence-based assessments.
- Federal Oversight: Alexandre Bergeron, spokesperson for federal Health Minister Marjorie Michel, affirmed Ottawa's commitment to dementia support programs, emphasizing that health officials are actively guided by the Ministerial Advisory Board on Dementia to identify care priorities.
Why dismissing memory loss as normal aging is now costlier than ever
In many Nigerian and broader African households, noticeable memory loss in elders is often brushed aside as a natural consequence of growing old, or kept quiet because of cultural discomfort around cognitive illness. Medical specialists note that normalizing significant memory impairment keeps families from seeking medical attention early. Now that therapies exist to meaningfully slow down Alzheimer's progression, treating memory loss as merely an inevitable part of aging carries a permanent cost.
Because these newly approved medications only work before extensive neurodegeneration occurs, understanding the difference between normal aging and clinical decline is critical. Minor lapses, such as occasionally forgetting a name, can happen with age. However, consistent difficulty with comprehension, familiar routines, or recognizing everyday items indicates a medical condition that needs testing. Overcoming the instinct to downplay these symptoms within our families is essential if loved ones are to qualify for treatment before the window closes.
Have you dismissed an older relative's noticeable memory lapses as harmless aging, and is it time to encourage a formal doctor's assessment?
Conclusion
The impending commercial entry of lecanemab and donanemab represents an important milestone in modern Alzheimer's treatment, but medical innovation alone cannot overcome an unprepared health architecture. With public pricing negotiations underway and individual provinces deciding whether these drugs will be placed on public formularies, Canada faces a critical 12 to 18-month window. Health ministries must use this preparatory period to eliminate long diagnostic waiting lists, build functional infusion networks, and establish equitable regional care corridors—ensuring that early-stage patients can access these therapies before disease progression shuts the window of opportunity.
Reporting based on coverage by Global News Canada.
Category: Health